The 2th phase of the test of The Oral Psoriasis drug BMS-986165 of Boxei Squibb achieved positive results

psoriasis is a chronic immune disease that occurs on the skinIt is a noncommunicable disease that accelerates the growth cycle of skin cells and causes thick scabs of skin to appearrecently, The BMS announced its oral psoriasisdrug(completed a phase 2trialon plaque psoriasis (results show that patients reached a high level of skin damage removal rate after 3 months of daily treatment)THE BMS

(WHICH HAS INDICATED THAT IT IS BEGINNING TO RECRUIT PATIENTS WITH MODERATE TO SEVERE PSORIASIS FOR A PHASE 3 CLINICAL STUDY OF THE DRUGPhase 2 trials of the drug for lupus and Crohn's disease are also under way, and the company is planning to study the benefits of the drug's treatment in a variety of immuno-mediated diseases2 phase of clinical studies randomly assigned 267 patients to different doses of oral drug groups and placebo control groupsthe study reached its main endpoint: 66-75% of patients who received 3mg of the drug twice or more a day had at least 75% of the skin removal rate after 12 weeks, and 44% showed a 90% skin loss removal rate, compared with 7% of those who took a placeboIn 25% of patients (treated with a maximum dose of 12 mg per day) the skin damage removal rate reached 100%Tyk2 is a member of the JAK family (other members include JAK1, JAK2 and JAK3) and is responsible for participating in IFN-alpha, IL-6, IL-10 and IL-12 signal conductionThe gene is responsible for encoding tyrosine kinases and, more specifically, members of the Janus kinase (JAKs) protein familyTyk2 can phosphate the STAT protein downstream of IL-12, IL-23 and Type I interferon receptorsTyk2 genetic variation is associated with a variety of autoimmune diseases, and inactivated coding mutations can lead to a variety of immunomediated diseases, including systemic lupus erythematosus (SLE)as a highly selective and effective small molecule inhibitor, BMS-986165 blocks receptor-mediated Tyk2 activation by stabilizing the protein's regulatory pseudokinase domain